Shibata, Kazuhiko

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 4,090

Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00–03

Teramukai, S., Kitano, T., Kishida, Y., Kawahara, M., Kubota, K., Komuta, K., Minato, K., Mio, T., Fujita, Y., Yonei, T., et al. (2009) · European Journal of Cancer

Inflammatory Biomarkers in Disease PrognosisLung Cancer Research Studies

Cited by 344

Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03

Kishida, Y., Kawahara, M., Teramukai, S., Kubota, K., Komuta, K., Minato, K., Mio, T., Fujita, Y., Yonei, T., Nakano, K., et al. (2009) · British Journal of Cancer

Lung Cancer Diagnosis and TreatmentLung Cancer Treatments and Mutations

Cited by 87